Evofem Biosciences, Inc. (EVFM)
Evofem Biosciences, Inc. (EVFM)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Gain on debt extinguishment | NaN | NaN | NaN | 0 |
| Net loss on disposal or impairment of property and equipment | NaN | 0 | 0 | -20 |
| Net income (loss) | -5,465 | 2,788 | -1,569 | -828 |
| Gain on accounts payable and accrued expenses settlements | NaN | 18 | 11 | 5,607 |
| Gain on change in accounting estimates on contingent royalty liability | NaN | 0 | 1,933 | NaN |
| Change in fair value of financial instruments | -162 | 131 | -1,845 | 1,355 |
| Inventory write-down for excess & obsolescence | 192 | 834 | 0 | 178 |
| Loss on contingent liability | 58 | 29 | 0 | 25 |
| Loss on issuance of financial instruments | NaN | NaN | NaN | 0 |
| Stock-based compensation | 15 | 42 | 23 | 101 |
| Depreciation | 4 | 5 | 4 | 10 |
| Amortization of intangible asset | 75 | 89 | 80 | 330 |
| Noncash interest expense | 614 | 606 | 595 | 1,165 |
| Noncash right-of-use asset amortization | 32 | 13 | 34 | 61 |
| Trade accounts receivable | -11,920 | 8,045 | -499 | -4,898 |
| Inventories | 761 | -25 | -222 | 507 |
| Prepaid and other assets | 130 | 144 | -423 | -77 |
| Accounts payable | -1,605 | 1,547 | -656 | -709 |
| Accrued expenses and other liabilities | -1,636 | 3,452 | 502 | 514 |
| Accrued compensation | -1,092 | -1,022 | 360 | -245 |
| Contingent liabilities | -50 | -24 | -50 | -425 |
| Operating lease liabilities | -32 | -15 | -32 | -62 |
| Net cash and cash equivalents and net restricted cash and cash equivalents provided by operating activities | 2,301 | 31 | 336 | -2,359 |
| Payments related to asset acquisition | NaN | NaN | 0 | 57 |
| Payments related to intangible asset acquisition | NaN | 57 | NaN | NaN |
| Purchases of property and equipment | 2 | 3 | 0 | 2 |
| Net cash and cash equivalents and net restricted cash and cash equivalents used in investing activities | -2 | -3 | 0 | -59 |
| Borrowings under short-term debt | NaN | 0 | 0 | 383 |
| Proceeds from issuance of aditxt notes related party | NaN | 0 | 0 | 2,425 |
| Payments under short term debt and notes carried at fair value | 498 | 278 | 244 | 383 |
| Proceeds from reinstatement of merger agreement related party | NaN | NaN | NaN | 0 |
| Cash paid for financing costs | NaN | 12 | NaN | NaN |
| Net cash and cash equivalents and net restricted cash and cash equivalents used in financing activities | -498 | -290 | -244 | 2,425 |
| Net change in cash and cash equivalents and net restricted cash and cash equivalents | 1,801 | -262 | 92 | 7 |
| Cash and cash equivalents and restricted cash and cash equivalents beginning of period | 578 | 840 | 741 | NaN |
| Cash, cash equivalents and restricted cash and cash equivalents end of period | 2,379 | 578 | 840 | NaN |